Evaluation of Microrna Expression Pattern (Mir-28, Mir-181A, Mir-34A, and Mir-31) in Patients With Covid-19 Admitted to Icu and Diabetic Covid-19 Patients Publisher Pubmed



Khatami A¹ ; Taghizadieh M² ; Nahand JS³ ; Karimzadeh M^{4, 5} ; Kiani SJ¹ ; Khanaliha K⁶ ; Kalantari S⁷ ; Chavoshpour S⁸ ; Mirzaei H⁹ ; Donyavi T¹⁰ ; Bokharaeisalim F¹ Show Affiliations
Source: Intervirology Published:2023

Abstract

Introduction: MicroRNAs, or miRNAs, with regulatory performance in inflammatory responses and infection are the prevalent manifestations of severe coronavirus disease (COVID-19). This study aimed to evaluate whether PBMC miRNAs are diagnostic biomarkers to screen the ICU COVID-19 and diabetic COVID-19 subjects. Methods: Candidate miRNAs were selected through previous studies, and then the PBMC levels of selected miRNAs (miR-28, miR-31, miR-34a, and miR-181a) were measured via quantitative reverse transcription PCR. The diagnostic value of miRNAs was determined by the receiver operating characteristic (ROC) curve. The bioinformatics analysis was utilized to predict the DEM genes and relevant bio-functions. Results: The COVID-19 patients admitted to ICU had significantly greater levels of selected miRNAs compared to non-hospitalized COVID-19 and healthy people. Besides, the mean miR-28 and miR-34a expression levels in the diabetic COVID-19 group were significantly upregulated when compared with the non-diabetic COVID-19 group. ROC analyses demonstrated the role of miR-28, miR-34a, and miR-181a as new biomarkers to discriminate the non-hospitalized COVID-19 group from the COVID-19 patients admitted to ICU samples, and also miR-34a can probably act as a useful biomarker for screening diabetic COVID-19 patients. Using bioinformatics analyses, we found the performance of target transcripts in many bioprocesses and diverse metabolic routes such as the regulation of multiple inflammatory parameters. Discussion: The difference in miRNA expression patterns between the studied groups suggested that miR-28, miR-34a, and miR-181a could be helpful as potent biomarkers for diagnosing and controlling COVID-19. © 2023 The Author(s). Published by S. Karger AG, Basel.